HAND2-AS1 reverses lenvatinib resistance in hepatocellular carcinoma by promoting ferroptosis through the TLR4/NOX2/DUOX2 pathway via miR-219a-1-3p, with low HAND2-AS1 levels linked to early recurrence. Here, CYBB is linked to hepatocellular carcinoma.